We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

50 hedge funds and large institutions have $6.98M invested in AEON Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 55 → 50 (-5)

17% less capital invested

Capital invested by funds: $8.42M → $6.98M (-$1.44M)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
7
Closed
8
Calls
$1.04M
Puts
–
Net Calls
+$1.04M
Net Calls Change
-$67K

Top Buyers

Rank Fund Capital Flow
1
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$153K
2
AC
Aristeia Capital
Connecticut
+$138K
3
CF
Cantor Fitzgerald
New York
+$22K
4
Nomura Holdings
Nomura Holdings
Japan
+$12.3K
5
CC
Centiva Capital
New York
+$6.88K

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$87K
2
Blackstone Inc
Blackstone Inc
New York
-$85K
3
ICMH
Integrity Capital Management (HK)
Hong Kong
-$35K
4
RA
Ramius Advisors
New York
-$35K
5
WAM
Wolverine Asset Management
Illinois
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2.83M – – –
LP
2
LMR Partners
United Kingdom
$1.96M – – –
AC
3
Athos Capital
Hong Kong
$291K – – –
Parallax Volatility Advisers
4
Parallax Volatility Advisers
California
$241K +$153K +372,006 +95%
CC
5
Covalis Capital
United Kingdom
$180K – – –
SCM
6
Segantii Capital Management
Hong Kong
$163K – – –
ECP
7
Empyrean Capital Partners
California
$147K – – –
AC
8
Aristeia Capital
Connecticut
$105K +$138K +333,333 New
DKCM
9
Davidson Kempner Capital Management
New York
$103K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$88K -$19.2K -46,618 -14%
SCM
11
Shaolin Capital Management
Florida
$81K – – –
PC
12
Periscope Capital
Ontario, Canada
$79K – – –
FTCM
13
Fir Tree Capital Management
New York
$50K – – –
TCM
14
Tenor Capital Management
New York
$50K – – –
KC
15
Kepos Capital
New York
$48K – – –
QGA
16
Q Global Advisors
Texas
$40K – – –
CH
17
CVI Holdings
Delaware
$39K -$10.7K -25,913 -16%
CF
18
Cantor Fitzgerald
New York
$39K +$22K +53,259 +69%
PMAM
19
Picton Mahoney Asset Management
Ontario, Canada
$36K – – –
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$30K – – –
Verition Fund Management
21
Verition Fund Management
Connecticut
$30K +$400 +969 +1%
WA
22
Whitebox Advisors
Minnesota
$28K -$3.3K -8,000 -8%
Wells Fargo
23
Wells Fargo
California
$28K – – –
CCA
24
Castle Creek Arbitrage
Colorado
$26K – – –
SCC
25
Spring Creek Capital
Kansas
$26K – – –
1
2 3

AEON.WS Hedge Fund Activity: Q1 2022 in Review

50 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2022, worth a combined $6.98M — down 17% from $8.42M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of AEON.WS and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Parallax Volatility Advisers, adding an estimated $153K. The largest seller was UBS O'Connor, exiting entirely with an estimated $87K sold.

  • 50 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2022, down from 55 in Q4 2021.
  • Funds reported $6.98M of AEON Biopharma Inc stock for Q1 2022, down 17% quarter-over-quarter.
  • 3 funds opened new AEON Biopharma Inc positions in Q1 2022 and 8 closed out, a net change of -5 holders.
  • The largest AEON Biopharma Inc buyer in Q1 2022 was Parallax Volatility Advisers, an estimated $153K added.
  • The largest AEON Biopharma Inc seller in Q1 2022 was UBS O'Connor, an estimated $87K sold.

Based on aggregated 13F filings for Q1 2022.